Specifically, the Phase I/II clinical trial in MPSVI patients (NCT03173521) demonstrated the safety and efficacy of this gene therapy, with sustained ARSB protein levels for at least 3 years (Brunetti-Pierri et al. 2022; Rossi et al. 2024). This evidence concerns the gene ARSB and mucopolysaccharidosis type 6.